The 34th ESCMID Global conference in Barcelona showcased significant advancements in molecular diagnostics and infectious disease management, with notable product launches and discussions.
Roche, post its acquisition of GenMark, introduced the cobas eplex system, previously known as the ePlex® system, under its cobas brand. This rebranded molecular diagnostic platform underscores Roche’s commitment to enhancing product quality and improving healthcare outcomes. The cobas eplex system offers syndromic panels for rapid and comprehensive diagnosis of various pathogens causing infections, particularly focusing on respiratory and bloodstream infections. Its incorporation of molecular technologies ensures accurate detection, with plans for expansion into gastrointestinal, meningitis, and encephalitis infections. Key features such as on-board quality control tracking and customizable comments facilitate treatment decisions, maximizing patient benefits of rapid, syndromic molecular diagnostics.
At the conference, MGI Tech unveiled its DNBSEQ-E25 sequencing platform, further emphasizing the pivotal role of molecular technologies in infectious disease research and diagnostics. This portable sequencing solution offers high-throughput capabilities, making it suitable for analyzing complex microbial genomes and identifying genetic variations associated with infectious diseases. MGI’s partnership with ABL Diagnostics aims to broaden access to Next Generation Sequencing (NGS) technology for microbiology genotyping, covering various infectious diseases applications.
Deepull unveils UllCORE, a benchtop diagnostic system for rapid pathogen identification in sepsis and acute infections. UllCORE delivers 50 reportable results in one hour, covering 95% of sepsis-causing pathogens and resistance genes, bypassing lengthy blood culture processes. With real-time multiplex PCR, it extracts microbial DNA from whole blood, aiding in early sepsis detection. The system aims to enhance treatment decisions, combat antimicrobial resistance, and potentially revolutionize sepsis diagnosis globally. Driven by years of research and bolstered by expert appointments, UllCORE’s debut at ESCMID Global 2024 marks a significant milestone in deepull’s mission to transform sepsis care.
The ESCMID Global conference highlighted the importance of molecular technologies in advancing infectious disease diagnostics, surveillance, and management. The integration of molecular diagnostics into platforms like the cobas eplex system and the launch of innovative sequencing platforms underscore the industry’s commitment to leveraging cutting-edge technology to address complex healthcare challenges and improve patient outcomes.